Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
President Trump demands drugmakers slash prices within 60 days
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
Pfizer: Seagen Acquisition Starting To Bear Fruit
Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition
Cramer names biopharma companies to watch as industry mergers start to pile up
5 Biotech Acquisition Targets To Accumulate In 2024
Pfizer Completes Acquisition of Seagen
Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen
8 Tax-Loss Sell Alerts For December
Pfizer to close Seagen acquisition after donating cancer drug rights
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
Pfizer expects to close Seagen deal on Thursday, will create a new oncology division to incorporate company
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
Seagen's (SGEN) Combo Drug Expanded-Use sBLA Gets Priority Tag
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross' Tongue
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
This High-Yield Dividend Stock Is a Proven Wealth Creator
Seagen 3Q revenue beat driven by jump in product sales
Seattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to Say
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Pfizer wins unconditional EU antitrust okay for $43 bln Seagen buy
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023
5 Stocks That Have Massive Upside According to Analysts
Signal Says Buy Calls on This Biotech Stock
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Flee to Healthcare Stocks if Recession Rears its Head?
EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy